» Articles » PMID: 28668075

MiRNome Landscape Analysis Reveals a 30 MiRNA Core in Retinoblastoma

Abstract

Background: miRNAs exert their effect through a negative regulatory mechanism silencing expression upon hybridizing to their target mRNA, and have a prominent position in the control of many cellular processes including carcinogenesis. Previous miRNA studies on retinoblastoma (Rb) have been limited to specific miRNAs reported in other tumors or to medium density arrays. Here we report expression analysis of the whole miRNome on 12 retinoblastoma tumor samples using a high throughput microarray platform including 2578 mature miRNAs.

Methods: Twelve retinoblastoma tumor samples were analyzed using an Affymetrix platform including 2578 mature miRNAs. We applied RMA analysis to normalize raw data, obtained categorical data from detection call values, and also used signal intensity derived expression data. We used Diana-Tools-microT-CDS to find miRNA targets and ChromDraw to map miRNAs in chromosomes.

Results: We discovered a core-cluster of 30 miRNAs that were highly expressed in all the cases and a cluster of 993 miRNAs that were uniformly absent in all cases. Another 1022 miRNA were variably present in the samples reflecting heterogeneity between tumors. We explored mRNA targets, pathways and biological processes affected by some of these miRNAs. We propose that the core-cluster of 30 miRs represent miRNA machinery common to all Rb, and affecting most pathways considered hallmarks of cancer. In this core, we identified miR-3613 as a potential and critical down regulatory hub, because it is highly expressed in all the samples and its potential mRNA targets include at least 36 tumor suppressor genes, including RB1. In the variably expressed miRNA, 36 were differentially expressed between males and females. Some of the potential pathways targeted by these 36 miRNAs were associated with hormonal production.

Conclusion: These findings indicate that Rb tumor samples share a common miRNA expression profile regardless of tumor heterogeneity, and shed light on potential novel therapeutic targets such as mir-3613 This is the first work to delineate the miRNA landscape in retinoblastoma tumor samples using an unbiased approach.

Citing Articles

Ago2/CAV1 interaction potentiates metastasis via controlling Ago2 localization and miRNA action.

Lin M, Kuo W, Chen S, Hsu J, Lu L, Wang C EMBO Rep. 2024; 25(5):2441-2478.

PMID: 38649663 PMC: 11094075. DOI: 10.1038/s44319-024-00132-7.


The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma.

Yan L, Lin H, Yu H, Jie L, Chen J, Mei Y J Med Biochem. 2022; 41(4):497-505.

PMID: 36381083 PMC: 9618339. DOI: 10.5937/jomb0-34794.


Retrospective Evaluation of Somatic Alterations in Cell-Free DNA from Blood in Retinoblastoma.

Abramson D, Mandelker D, Francis J, Dunkel I, Brannon A, Benayed R Ophthalmol Sci. 2022; 1(1):100015.

PMID: 36246006 PMC: 9560572. DOI: 10.1016/j.xops.2021.100015.


Integrated analysis of multiple bioinformatics studies to identify microRNA-target gene-transcription factor regulatory networks in retinoblastoma.

Wen Y, Zhu M, Zhang X, Xiao H, Wei Y, Zhao P Transl Cancer Res. 2022; 11(7):2225-2237.

PMID: 35966326 PMC: 9372260. DOI: 10.21037/tcr-21-1748.


miR-141-3p promotes retinoblastoma progression inhibiting sushi domain-containing protein 2.

Liu S, Wen C Bioengineered. 2022; 13(3):7410-7424.

PMID: 35259051 PMC: 8973658. DOI: 10.1080/21655979.2022.2048770.


References
1.
Chatterjee A, Leichter A, Fan V, Tsai P, Purcell R, Sullivan M . A cross comparison of technologies for the detection of microRNAs in clinical FFPE samples of hepatoblastoma patients. Sci Rep. 2015; 5:10438. PMC: 4453922. DOI: 10.1038/srep10438. View

2.
Xu X, Jia R, Zhou Y, Song X, Wang J, Qian G . Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 2011; 38(5):1385-93. DOI: 10.3892/ijo.2011.961. View

3.
He L, Thomson J, Hemann M, Hernando-Monge E, Mu D, Goodson S . A microRNA polycistron as a potential human oncogene. Nature. 2005; 435(7043):828-33. PMC: 4599349. DOI: 10.1038/nature03552. View

4.
Jenkinson H . Retinoblastoma: diagnosis and management--the UK perspective. Arch Dis Child. 2015; 100(11):1070-5. DOI: 10.1136/archdischild-2014-306208. View

5.
Liu W, Mei R, Di X, Ryder T, Hubbell E, Dee S . Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics. 2002; 18(12):1593-9. DOI: 10.1093/bioinformatics/18.12.1593. View